3 hours ago
1
Sarah Silbiger/Getty Images News
Praxis Precision Medicines (PRAX) on Tuesday announced an accelerated timeline in the development of its anti-seizure therapy, relutrigine, following positive feedback from the U.S. FDA.
The Boston, Massachusetts-based biotech said that during a recent Type B meeting, it has aligned with the
English (US) ·